Norma N. Anderson

TL;DR: Through application of stringent combinatorial criteria, the transgenic/knockout approach allows identification of genes whose activities are likely to be controlled directly by one family of transcription factors, in this case the SREBPs.

TL;DR: It is shown that purified PCSK9 added to the medium of HepG2 cells reduces the number of cell-surface LDLRs in a dose- and time-dependent manner and associates with the LDLR and reduces hepatic LDLR protein levels.

TL;DR: PCSK9 targeting with RNAi therapeutics as an approach to specifically lower LDLc is validated, paving the way for the development of PCSK9-lowering agents as a future strategy for treatment of hypercholesterolemia.

TL;DR: In this article, a liver-specific inhibitor of acetyl-CoA carboxylase (ACC1) and (ACC2), enzymes that produce malonyl CoA for fatty acid synthesis, was developed to determine if reducing lipogenesis functions similarly in humans.

TL;DR: A role for miR-148a is uncovered as a key regulator of hepatic LDL-C clearance through direct modulation of LDLR expression and the therapeutic potential of inhibiting miR -148a to ameliorate an elevated LDL/HDL-C ratio, a prominent risk factor for cardiovascular disease is demonstrated.